Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.
Author(s): Guinea J, Recio S, Pelaez T, Torres-Narbona M, Bouza E
Affiliation(s): Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, Universidad Complutense de Madrid, Madrid, Spain. jguineaortega@yahoo.es
Publication date & source: 2008-09, Antimicrob Agents Chemother., 52(9):3444-6. Epub 2008 Jul 7.
Publication type: Research Support, Non-U.S. Gov't
We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 microg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of <or=2 microg/ml.
|